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Duchenne and Becker muscular dystrophy (DMD/BMD) comprise a spectrum of
devastating X-linked muscle wasting disease for which there is no treatment. DMD/BMD
is caused by mutations in the gene encoding dystrophin, a cytoskeletal protein that
stabilizes the muscle membrane and also targets other proteins to the sarcolemma.
Among these is the muscle-specific isoform of neuronal nitric oxide synthase (nNOSμ)
which binds spectrin-like repeats within dystrophin’s rod domain and the adaptor protein
α-syntrophin. Dystrophin deficiency causes loss of sarcolemmal nNOSμ and reduces
paracrine signaling of muscle-derived nitric oxide (NO) to the microvasculature, which
renders the diseased muscle fibers susceptible to functional muscle ischemia during
exercise. Repeated bouts of functional ischemia superimposed on muscle fibers already
weakened by dystrophin deficiency result in use-dependent focal muscle injury. Genetic
and pharmacologic strategies to boost nNOSμ-NO signaling in dystrophic muscle alleviate
functional muscle ischemia and show promise as novel therapeutic interventions for the
treatment of DMD/BMD.
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Duchenne and Becker muscular dystrophy (DMD/BMD) com-
prise a spectrum of devastating X-linked muscle wasting disease
accounting for over 80% of all cases of muscular dystrophy
(Bushby et al., 2010a). In DMD, boys are diagnosed as tod-
dlers and most are wheelchair bound by age 15. Death often
occurs by age 20 from respiratory complications or cardiomy-
opathy. More patients survive to age 30 due to home ventilation
and corticosteroids, which can prolong ambulation by 2–3 years,
reduce risk of scoliosis, and mitigate pulmonary and cardiac
decline in the second decade (Bushby et al., 2010a,b). Despite
this demonstrated efficacy, more than 25% of boys with DMD
are not treated with corticosteroids due to intolerable side-effects
or lack of response (Bushby et al., 2010a,b). In BMD, the disease
is milder and more clinically heterogenous than DMD. Muscle
weakness often is first noticed in adolescence or young adulthood.
Cardiac decline in BMD patients may surpass skeletal muscle
decline, with death from cardiomyopathy often occurring before
age 60 (Bushby et al., 2010a). There is a clear need for addi-
tional therapeutic strategies to manage the clinical challenges of
DMD/BMD.
More than 25 years have passed since mutations in the DMD
gene were discovered to cause DMD/BMD (Monaco et al., 1986;
Koenig et al., 1987). Mutations resulting in the absence of a
functional dystrophin protein cause DMD, whereas mutations
resulting in a reduced amount or shortened dystrophin protein
cause BMD. Dystrophin is a large (427 kDa) sub-sarcolemmal
protein that provides a physical link between the intracellular
actin cytoskeleton and the extracellular matrix (Blake et al., 2002).
Loss of dystrophin destabilizes the sarcolemma, rendering the
muscle fibers susceptible to injury during contraction (Petrof
et al., 1993). Repeated cycles of necrosis followed by regenera-
tion lead to satellite cell depletion and gradual replacement of
muscle by fat and connective tissue, manifesting clinically as
progressive muscle wasting and weakness (Blake et al., 2002).
Dystrophin also is a scaffolding protein that localizes other struc-
tural and signaling proteins to the sarcolemma, forming a highly
organized multimeric dystrophin-associated glycoprotein com-
plex (DGC) (Blake et al., 2002). Dystrophin deficiency disrupts
the DGC, resulting in the absence, downregulation, or mislocal-
ization of the dystrophin-associated proteins. Thus, numerous
pathogenetic mechanisms are likely activated in dystrophin-
deficient muscle in response to disruption of the sarcolemmal
DGC. Identifying the key mechanistic link(s) between loss of dys-
trophin and the clinical phenotype of DMD/BMD has been a
major focus of research efforts with the ultimate goal of discov-
ering new therapeutic targets to slow or prevent the dystrophic
process.
THE VASCULAR HYPOTHESIS OF DMD
One putative mechanism that has received increased attention
recently is muscle ischemia. One of the earliest histological
changes seen in dystrophic muscle, even before the onset of signif-
icant muscle weakness, is the appearance of small random groups
of muscle fibers at the same stage of necrosis or regeneration
surrounded by histologically normal muscle fibers (Engel, 1967).
In the pre-dystrophin era, it was proposed that this characteris-
tic focal necrosis might reflect local microvascular ischemia. The
idea was that vascular insufficiency at the level of the microcir-
culation caused selective infarction of only those muscle fibers
supplied by the obstructed blood vessels, while nearby fibers
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supplied by unobstructed vessels were not affected (Bramwell,
1925; Demos and Escoiffier, 1957; Cazzato, 1968). Initial exper-
imental support for this vascular hypothesis came from studies
performed more than 40 years ago in which the characteristic
focal lesions of DMD muscle were reproduced in the muscles
of healthy animals by occlusion of intramuscular arterioles with
dextran beads, or by functional ischemia induced by a combina-
tion of arterial ligation and vasoconstrictor injection (Hathaway
et al., 1970; Mendell et al., 1971, 1972). However, subsequent
morphological studies did not reveal any fixed anatomical abnor-
malities in the skeletal muscle microcirculation of DMD patients,
with the exception of replication of the capillary basal lam-
ina (Jerusalem et al., 1974; Musch et al., 1975; Koehler, 1977;
Leinonen et al., 1979). In addition, findings from studies of skele-
tal muscle blood flow in DMD patients were equivocal, indicating
that blood flow to resting muscle was decreased, increased, or
normal (Demos, 1961; Emery and Schelling, 1965; Kapuscinska
et al., 1970; Paulson et al., 1974; Bradley et al., 1975; Leinonen
et al., 1979). The lack of any identifiable cause of muscle ischemia
in DMD patients diminished enthusiasm for the vascular
hypothesis.
FUNCTIONAL MUSCLE ISCHEMIA DUE TO LOSS OF
SARCOLEMMAL nNOSµ
It was not until after the discovery of dystrophin and the DGC
that the vascular hypothesis re-emerged. Among the dystrophin-
associated proteins is neuronal nitric oxide synthase μ (nNOSμ),
a muscle-specific splice variant of NOS, which is recruited to the
sarcolemma by two independent interactions involving its PDZ
(post-synaptic density 95, discs large, and zonula occludens-1)
domain. The nNOSμ PDZ β-finger interacts with the PDZ
domain of the adaptor protein α-syntrophin, which binds to
dystrophin’s C-terminal domain, while the nNOSμ PDZ groove
interacts with spectrin-like repeats 16 and 17 (R16/17) within
dystrophin’s rod domain (Brenman et al., 1995; Chang et al.,
1996; Lai et al., 2009, 2013). Dystrophin deficiency causes nNOSμ
to be misplaced from the sarcolemma to the cytosol where the
residual amount of protein is also greatly reduced (Brenman
et al., 1995; Chang et al., 1996; Chao et al., 1996; Torelli et al.,
2004; Kobayashi et al., 2008). Parallel translational experiments
in mouse models and boys with DMD showed that loss of sar-
colemmal nNOSμ renders the dystrophin-deficient muscle fibers
susceptible to muscle ischemia during exercise (Thomas et al.,
1998, 2003; Sander et al., 2000; Lai et al., 2009). As shown in
Figure 1, NO produced by sarcolemmal nNOSμ normally acts as
a local paracrine signal that optimizes blood flow in the working
muscles by attenuating sympathetic (i.e., α-adrenergic) vasocon-
striction (Thomas and Victor, 1998; Thomas et al., 1998, 2003;
Sander et al., 2000; Chavoshan et al., 2002). This protective mech-
anism, termed functional sympatholysis, is impaired in the mdx
mouse model of DMD, in boys with DMD, and in men with
BMD, resulting in functional muscle ischemia due to unopposed
sympathetic vasoconstriction (Thomas et al., 1998; Sander et al.,
2000; Martin et al., 2012). A similar impairment is present in the
contracting muscles of nNOS null mice, indicating that the defec-
tive vasoregulation in dystrophin-deficient muscle is likely due
to the loss of sarcolemmal nNOSμ (Thomas et al., 1998). This
is further substantiated by proof-of-concept experiments in α-
syntrophin null mice and in transgenic mice expressing a mutated
α-syntrophin lacking its PDZ domain, both of which are charac-
terized by a selective reduction of sarcolemmal, but not cytosolic,
nNOSμ (Kameya et al., 1999; Adams et al., 2001; Thomas et al.,
2003). These mice also display an impaired NO-dependent mod-
ulation of α-adrenergic vasoconstriction in contracting skeletal
muscle, a defect that is corrected by the reestablishment of nor-
mal levels of sarcolemmal nNOSμ in transgenic mice expressing
full-length α-syntrophin (Thomas et al., 2003). Furthermore, in
mdx mice functional muscle ischemia is alleviated and exercise
tolerance is improved by expression of a R16/17-containing syn-
thetic dystrophin minigene that restores sarcolemmal nNOSμ
(Lai et al., 2009; Zhang et al., 2013). In contrast, muscle ischemia
persists in mdx mice expressing a R16/17-lacking dystrophin
minigene that restores all of the DGC except nNOSμ (Lai et al.,
2009).
Collectively, these observations in numerous mouse models
and in DMD/BMD patients have advanced the concept that NO
produced by sarcolemmal nNOSμ helps to regulate blood flow
in active muscle by blunting the potentially deleterious effect of
sympathetic activation during exercise. The loss of this protective
mechanism may leave dystrophin-deficient skeletal muscle vul-
nerable to recurrent bouts of ischemia, thereby promoting muscle
fatigue and exacerbating use-dependent muscle injury (Rando,
2001; Asai et al., 2007). Consistent with this hypothesis, mdx
mice display an exaggerated exercise-induced fatigue response
that is associated with reduced muscle perfusion and increased
focal constriction of muscle microvessels (Kobayashi et al., 2008).
The exaggerated fatigue response in the mdx mice appears to be
due to the loss of sarcolemmal nNOSμ, as excessive fatigue also
is observed in nNOS null mice and in wild type mice treated
with a nNOS-specific inhibitor (Kobayashi et al., 2008). Reduced
NO signaling also contributes to contraction-induced injury of
dystrophin-deficient muscle. Mdx muscle exhibits progressive
damage post-contraction that can be alleviated by treatment with
a NO donor (Asai et al., 2007). Thus, the updated version of the
vascular hypothesis of DMD suggests that the nNOSμ-NO path-
way could be considered as a potential new drug target to slow
disease progression in DMD/BMD patients.
However, many questions remain about the nature of the
ischemic stimulus and the long term effects of ischemia on
dystrophic muscle. For example, vasoconstrictor responses to
activation of sympathetic nerves are reduced in the resting cre-
master muscles of mdx mice (Bagher et al., 2011), suggesting that
there may be less sympathetic vasoconstriction to oppose during
exercise. While this does not appear to be the case in the fore-
arm muscles of DMD/BMD patients (Sander et al., 2000; Martin
et al., 2012), studies of other muscles including locomotor mus-
cles are warranted.Whether othermetabolic vasodilator pathways
independent of nNOSμ-NO (e.g., H+, K+, ATP) are impaired
and contribute to functional ischemia has yet to be explored in
dystrophic muscle. Also unknown is if functional ischemia mani-
fests primarily as maldistribution of blood flow within the active
muscles or as reduced total muscle blood flow. Compensatory
mechanisms such as angiogenesis that are engaged to counteract
muscle ischemia appear to be robust in young mdx mice (Straino
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FIGURE 1 | Left panel, in healthy muscle, nNOSμ is localized to the
sarcolemma by association with the rod domain of dystrophin and the
PDZ domain of α-syntrophin (syn). During muscle contraction, some of
the nNOSμ-derived nitric oxide (NO) diffuses to the nearby
microvessels where it increases cGMP and attenuates norepinephrine
(NE)-mediated vasoconstriction. This NO-mediated functional
sympatholysis optimizes blood flow in the working muscles. Right
panel, in dystrophic muscle, nNOSμ is reduced in amount and
mislocalized from the sarcolemma to the cytosol. Less NO is
generated during muscle contraction, resulting in unrestrained
sympathetic vasoconstriction and transient functional muscle ischemia,
which may exacerbate injury of the diseased muscle fibers. Genetic
and pharmacologic interventions targeting different aspects of
nNOSμ-NO signaling that alleviate functional muscle ischemia in
preclinical studies are shown. sGC, soluble guanylyl cyclase; DG,
dystroglycan; PDE, phosphodiesterase.
et al., 2004), but impaired in older mdx mice (Palladino et al.,
2013), suggesting that the impact of muscle ischemia on disease
progression may vary over time.
RESTORING nNOSµ-NO SIGNALING TO ALLEVIATE MUSCLE
ISCHEMIA
In the absence of dystrophin, nNOSμ is both reduced in con-
tent and misplaced from the sarcolemma to the cytosol (Brenman
et al., 1995; Chang et al., 1996; Chao et al., 1996; Torelli et al.,
2004; Kobayashi et al., 2008). Feasible approaches to improve
NO signaling in dystrophic muscle have therefore focused largely
on providing exogenous NO, restoring normal levels and sar-
colemmal localization of nNOSμ, or enhancing effects of residual
cytosolic nNOSμ. Multiple genetic and pharmacologic strate-
gies that boost nNOSμ-NO signaling have been shown to ame-
liorate many features of the dystrophic phenotype—at least
in the mdx mouse. These strategies include genetic overex-
pression of NOS isoforms in muscle (Wehling et al., 2001;
Tidball and Wehling-Henricks, 2004; Wehling-Henricks et al.,
2005; Colussi et al., 2008), expression of dystrophin mini-genes
that restore sarcolemmal nNOSμ (Lai et al., 2009, 2013), sup-
plementation with the NOS substrate L-arginine to increase
endogenous NO production from cytosolic nNOSμ (Barton
et al., 2005; Voisin et al., 2005; Archer et al., 2006; Hnia et al.,
2008; Guerron et al., 2010), treatment with NO-donating drugs
(Marques et al., 2005; Brunelli et al., 2007; Benabdellah et al.,
2009; Mizunoya et al., 2011; Sciorati et al., 2011; Thomas et al.,
2012), and phosphodiesterase 5A (PDE5A) inhibition to pro-
long the half-life of cGMP arising from the residual NO gen-
erated by cytosolic nNOSμ (Asai et al., 2007; Kobayashi et al.,
2008).
There is evidence to suggest that some of the beneficial effects
of boosting nNOSμ-NO signaling in dystrophin-deficient muscle
are likely due to correction of the abnormal vascular pheno-
type of functional muscle ischemia. In the mdx mouse, PDE5A
inhibitors have been shown to ameliorate muscle ischemia, mus-
cle injury, and muscle fatigue after a brief bout of downhill exer-
cise (Kobayashi et al., 2008). In this seminal study by Kobayashi
and colleagues, the effect was dramatic and immediate and was
seen with two different PDE5A inhibitors, tadalafil and silde-
nafil. Acute tadalafil treatment has also been shown to reduce
contraction-induced injury in mdx mice, while chronic treat-
ment begun in utero improves muscle morphology, attenuates
sarcolemmal damage, and reduces muscle fibrosis (Asai et al.,
2007). Chronic sildenafil treatment has been shown to improve
cardiac dynamics in mdx mice and to rescue dystrophic skele-
tal muscle and prolong survival in a zebrafish model of DMD
(Khairallah et al., 2008; Adamo et al., 2010; Kawahara et al., 2011).
PDE5A inhibitors have proven to be safe and effective not
only for patients with erectile dysfunction but also for those
with pulmonary hypertension (Ravipati et al., 2007). Given the
encouraging findings of pre-clinical studies in the mdx mouse,
Martin and colleagues recently tested the translational potential
of PDE5A inhibition to benefit patients with muscular dystrophy
(Martin et al., 2012). They showed that treatment with a sin-
gle dose of tadalafil rescued the abnormal vascular phenotype in
the muscle of patients with BMD, fully restoring NO-dependent
modulation of reflex sympathetic vasoconstriction in the exer-
cising muscles. Tadalafil alleviated microvascular ischemia and
fully restored muscle blood flow regulation in 8 of the 9 BMD
patients studied (Martin et al., 2012). This finding is consistent
with the hypothesis that PDE5A inhibition boosts a residual
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NO-cGMP signal arising from nNOSμ misplaced to the cytosol
of dystrophin-deficient muscle. It is not clear why one patient
did not respond to tadalafil, but conceivably some patients with
DMD/BMD might have such a low level of residual muscle
nNOSμ that the NO-cGMP signal is insufficient for the PDE5A
inhibitor to boost. For such patients, NO-donating drugs could
offer an alternative approach to restore NO signaling.
The use of NO-donating drugs in muscular dystrophy was
first suggested in 2005 when Voisin and colleagues showed that
6 weeks of daily molsidomine treatment of mdx mice increased
muscle utrophin, reduced creatine kinase, and reduced mus-
cle necrosis (Voisin et al., 2005). Despite the beneficial effects
observed in this short-term study, molsidomine may not be the
best choice for long-term NO replacement in dystrophic mus-
cle because the drug is metabolized to SIN-1 in the liver, which
decomposes into NO and superoxide that can combine to form
the damaging free radical peroxynitrite (Singh et al., 1999). Over
time, this could be detrimental as dystrophin-deficient muscle
cells are highly sensitive to free radical injury (Rando, 2002).
Furthermore, unlike the PDE5A inhibitors, acute treatment with
molsidomine did not reduce exercise-induced fatigue in mdx
mice (Kobayashi et al., 2008).
Another class of NO-donating drug that has shown poten-
tial in pre-clinical mdx mouse studies is the cyclooxygenase
(COX)-inhibiting NO donor (CINOD) that combines a standard
COX inhibitor with a NO-donating moiety to produce dual phar-
macological action (Keeble andMoore, 2002;Wallace et al., 2009).
Chronic treatment (6–12 months) of mdx and α-sarcoglycan null
mice with the CINOD HCT 1026, a NO-donating flurbiprofen,
has been shown to improve muscle morphology and reduce mus-
cle necrosis, inflammation, and fatigue (Brunelli et al., 2007).
Similar effects have been observed in α-sarcoglycan null mice
treated with NCX 320, a NO-donating ibuprofen (Sciorati et al.,
2011). Improved muscle blood flow may contribute to the bene-
ficial effects of these drugs as short-term treatment for as little as
1 month with HCT 1026 reverses functional muscle ischemia in
mdx mice (Thomas et al., 2012). Importantly, the effect of HCT
1026 to prevent functional muscle ischemia does not abate with
prolonged treatment, negating the concern that tolerance to the
drug might develop with chronic use (Thomas et al., 2012). This
is a potential drawback for some commonly used NO donors such
as the organic nitrates (e.g., nitroglycerin), which lose vasodila-
tor potency during continuous exposure (Munzel et al., 2005).
Translational studies to determine if CINODs ameliorate func-
tional muscle ischemia have yet to be carried out in patients
with DMD/BMD. However, an initial 12-month pilot study has
shown that co-administration of the NO donor isosorbide dini-
trate and COX inhibitor ibuprofen is safe and well-tolerated in
adult dystrophic patients (D’Angelo et al., 2012).
While boosting nNOSμ-NO signaling appears to be an effec-
tive means to normalize muscle blood flow regulation in the
mdx mouse, it is likely to have additional mechanistic influences
as well. NO derived from nNOSμ has been shown to regulate
force generation, muscle mass, fatigue, muscle repair from injury,
oxidative stress, and inflammation (Stamler and Meissner, 2001;
Powers and Jackson, 2008). Thus, boosting NO signaling may
improve DMD/BMD by a variety of mechanisms that include:
(a) improving muscle blood flow and oxygen delivery (Thomas
et al., 1998; Sander et al., 2000; Asai et al., 2007; Kobayashi et al.,
2008; Martin et al., 2012); (b) decreasing muscle inflammation
(Brunelli et al., 2007; Lai et al., 2009; Sciorati et al., 2011); (c)
inhibiting histone deacetylase (HDAC) activity (Colussi et al.,
2008; Cacchiarelli et al., 2010); (d) reducing muscle fibrosis (Asai
et al., 2007; Guerron et al., 2010); (e) enhancing satellite cell
activation during muscle repair (Anderson, 2000; Brunelli et al.,
2007); (f) upregulating muscle utrophin—a dystrophin homolog
with functional similarities (Voisin et al., 2005; Hnia et al., 2008);
and (g) ameliorating cardiac dysfunction (Khairallah et al., 2008;
Adamo et al., 2010). Although the majority of studies to date have
reported favorable effects of boosting NO signaling in dystrophic
muscle, further careful analysis of the long-term effects of these
strategies is necessary as several studies have shown detrimental
effects of mislocalized NO signaling in skeletal muscle. Increased
cytosolic nNOSμ is postulated to mediate disuse muscle atro-
phy in normal mouse muscle by non-hemodynamic mechanisms
(e.g., involving Foxo transcription factors) (Suzuki et al., 2007)
and to reduce force production in dystrophic mouse muscle by
hypernitrosylation of ryanodine receptors (Li et al., 2011).
SUMMARY
Recent findings from preclinical studies in the mdx mouse and
clinical studies in DMD/BMD patients have led to renewed inter-
est in the vascular hypothesis of muscular dystrophy. The refined
hypothesis now provides a molecular mechanism, loss of sar-
colemmal nNOSμ and reduced paracrine NO signaling to the
muscle microvasculature, to explain the occurrence of functional
muscle ischemia in dystrophin-deficient muscle. Strategies to
restore nNOSμ-NO signaling in dystrophic muscle that alleviate
functional muscle ischemia include dystrophin minigene therapy,
PDE5A inhibition, and NO-donating drugs. The initial reports
showing largely beneficial effects of restoring NO signaling in dys-
trophic mouse muscle suggest that reducing muscle ischemia may
allow DMD/BMD patients to perform more work with less mus-
cle injury and fatigue, thereby slowing disease progression and
improving quality of life.
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